19 reports of this reaction
4.2% of all AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE reports
#5 most reported adverse reaction
MALIGNANT MELANOMA is the #5 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, manufactured by Kenvue Brands LLC. There are 19 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE to MALIGNANT MELANOMA. This represents approximately 4.2% of all 448 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE who experience malignant melanoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT MELANOMA is moderately reported among AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE users, representing a notable but not dominant share of adverse events.
In addition to malignant melanoma, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to malignant melanoma in FDA adverse event reports:
MALIGNANT MELANOMA has been reported as an adverse event in 19 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT MELANOMA accounts for approximately 4.2% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, making it a notable side effect.
If you experience malignant melanoma while taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.